April 26, 2004Neorx Corp • May 10th, 2005 • In vitro & in vivo diagnostic substances • Washington
On behalf of NeoRx Corporation, a Washington corporation (the “Company”), I am very pleased to extend to you an offer to join the Company as Chief Executive Officer. Subject to your agreement, evidenced by countersigning this letter, this letter agreement (this “Agreement”) sets forth the terms and conditions of your employment by the Company:
AMENDMENT NO. 1 TO NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and LINDA FINDLAY (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of February 28, 2003 (the “Agreement”) as follows:
AMENDMENT NO. 1 TO NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and ANNA WIGHT (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of February 28, 2003 (the “Agreement”) as follows:
AMENDMENT NO. 1 TO NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and KAREN AUDITORE-HARGREAVES (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of May 13, 2003 (the “Agreement”) as follows:
AMENDMENT NO. 1 TOKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and SUSAN D. BERLAND (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of October 25, 2004 (the “Agreement”) as follows:
